指南与共识精神分裂症与精神病性障碍会诊联络精神医学

多学科共识:氯氮平相关心肌炎的预防、筛查与监测及心肌炎后再挑战

Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis.
指南 / 共识 · Br J Psychiatry · 2025-06-02

该多学科国际共识通过系统文献检索和两轮Delphi流程,制定了氯氮平相关心肌炎(CAM)的诊断标准、氯氮平启动与再挑战方案。共识推荐比产品概要更慢的滴定方案以降低CAM风险,并制定最低与增强的筛查监测要求及再挑战方法。

要点

  • 推荐比产品概要更慢的氯氮平滴定方案以降低CAM风险。
  • CAM定义基于修改的欧洲心脏病学会免疫检查点抑制剂相关心肌炎临床标准。
  • 制定最低与增强的筛查监测要求,并详述CAM后再挑战方法。

核心结论

  • 该多学科项目为首个CAM指导文件,将帮助临床医生、照护者及患者,并促进国家指南制定。

研究设计与样本

  • Delphi小组由具有氯氮平或心肌炎专业知识的精神科医生、心内科医生、药师、精神药理学家和护士组成。

主要发现

  • 共识就基于修改的欧洲心脏病学会免疫检查点抑制剂相关心肌炎临床标准的CAM定义达成一致。
  • 推荐比氯氮平产品概要更慢的滴定方案以最小化CAM风险。
  • 制定了最低与增强的筛查监测要求以兼顾全球视角和某些医疗系统的有限资源,并详述了氯氮平再挑战方法。

关键数值与推荐

  • CAM定义依据修改的欧洲心脏病学会免疫检查点抑制剂相关心肌炎临床标准。
  • 推荐滴定方案慢于氯氮平产品概要所列方案。
  • 制定了最低与增强的筛查监测要求。

临床怎么用

  • 临床医生应采用比产品概要更慢的氯氮平滴定方案以降低CAM风险。
  • 按照共识的最低与增强要求对氯氮平使用者进行CAM筛查与监测。
  • 对发生CAM者,可参照共识详述的方法进行氯氮平再挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clozapine is the antipsychotic of choice for people with treatment-resistant schizophrenia (TRS) but is associated with the uncommon but potentially life-threatening adverse effect of myocarditis. However, there are no criteria for diagnosing clozapine-associated myocarditis (CAM) or global guidelines on detection and risk reduction, or for restarting clozapine after CAM. AIMS: To develop criteria for CAM and algorithms for clozapine initiation and clozapine rechallenge after CAM in a multiprofessional consensus process. METHOD: We conducted a systematic literature search for cases of clozapine rechallenge following CAM using the PubMed, EMBASE, CINAHL and PsycINFO databases, followed by a multidisciplinary international two-step Delphi consensus process in July and October 2024. The Delphi panel comprised psychiatrists, cardiologists, pharmacists, psychopharmacologists and nurses with expertise on clozapine or myocarditis. RESULTS: Ninety-three clinicians and academics with experience in prescribing clozapine from six continents participated in the Delphi process. A consensus was reached on a definition of CAM according to modified clinical criteria from the European Society of Cardiology for myocarditis associated with immune checkpoint inhibitors. Titration schemes slower than those given in the Summary of Product Characteristics for clozapine were recommended to minimise CAM risk. Minimum and enhanced requirements for screening and monitoring were developed to account for global perspectives and limited resources in certain healthcare systems, and an approach to clozapine rechallenge was elaborated. CONCLUSIONS: This multidisciplinary project represents the first guidance for CAM and will inform clinicians, other caregivers and patients, as well as facilitating the development of national guidelines on CAM prevention, screening and monitoring and rechallenge after an index episode of myocarditis in individuals taking clozapine.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wagner E, Korman N, Solmi M, et al. Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. Br J Psychiatry. 2025. PMID: 40452212. doi:10.1192/bjp.2025.89

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。